Boehringer Ingelheim Caps Patient Out-of-pocket Inhaler Costs at $35 per Month
Starting June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for all Boehringer Ingelheim inhalers, the company says.
Tag: Boehringer Ingelheim
All
Latest
All
LatestBoehringer’s Respimat Inhaler Gets Ease of Use Award
The Arthritis Foundation recognized Respimat with its Ease of Use Commendation for products proven to make life easier for people with arthritis and other physical limitations.
All
LatestPradaxa Approved for Treatment of Pulmonary Embolism and DVT
The FDA has approved Pradaxa (dabigatran etexilate mesylate) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in certain patients, according to Boehringer Ingelheim Pharmaceuticals.
